Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 12/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.54 |
| ▸ | CYP2E1 | P05181 | 5/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.54 |
| ▸ | CYP2B6 | P20813 | 5/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.41 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.40 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12195715 | 0.86 | CYP2A6 (0.57) | CYP2A6CYP3A4CYP2E1CYP2C9CYP2B6 | |
| SCHEMBL17060261 | 0.83 | CYP2A6 (0.57) | CYP2A6CYP3A4CYP2E1CYP2C9CYP2B6 | |
| SCHEMBL24318644 | 0.81 | CYP2A6 (0.50) | CYP2A6CYP3A4CYP2E1CYP2C9CYP2B6 | |
| SCHEMBL1425928 | 0.79 | KDM4E (0.45) | CYP2A6CYP3A4CYP2C9CYP2D6CYP2C19 | |
| SCHEMBL22300075 | 0.79 | ALOX5 (0.44) | CYP2A6CYP3A4CYP2E1CYP2C9CYP2B6 | |
| SCHEMBL14039824 | 0.75 | ESR1 (0.31) | CYP3A4CYP2C9CYP2C19CYP1A2KDM4E | |
| SCHEMBL6741567 | 0.74 | CYP2A6 (0.59) | CYP2A6CYP3A4CYP2E1CYP2C9CYP2B6 | |
| SCHEMBL15262718 | 0.72 | CYP2A6 (0.58) | CYP2A6CYP3A4CYP2E1CYP2C9CYP2B6 | |
| SCHEMBL17376763 | 0.71 | CYP2A6 (0.47) | CYP2A6CYP3A4CYP2E1CYP2C9CYP2B6 | |
| SCHEMBL3606167 | 0.70 | CYP2A6 (1.00) | CYP2A6CYP3A4CYP2E1CYP2C9CYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8481524-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-09 | — | — | US | disclosed |
| US-8481524-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-09 | — | — | US | disclosed |
| US-8481524-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-09 | — | — | US | disclosed |
| US-20110136789-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-09 | — | — | US | disclosed |
| US-20110136789-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-09 | — | — | US | disclosed |
| US-20110136789-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-09 | — | — | US | disclosed |
| EP-2205589-B1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMA (US) | 2011-03-23 | — | — | EP | disclosed |
| EP-2205589-B1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMA (US) | 2011-03-23 | — | — | EP | disclosed |
| CN-101990538-A | C-met protein kinase inhibitors | VERTEX PHARMA | 2011-03-23 | — | — | CN | disclosed |
| EP-2205589-A2 | C-MET PROTEIN KINASE INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2010-07-14 | — | — | EP | disclosed |
| WO-2009045992-A2 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-04-09 | — | — | WO | disclosed |
| WO-2009045992-A2 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136789-A1 | C-MET PROTEIN KINASE INHIBITORS | MET, PRKCH, ABL1 | CYP2A6 4181/4885CYP3A4 4344/4885CYP2E1 3783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.